{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+therapy+treatment&page=22",
    "query": {
      "intervention": "combined therapy treatment",
      "page": 22
    },
    "page_size": 10
  },
  "pagination": {
    "page": 22,
    "page_size": 10,
    "total_count": 12515,
    "total_pages": 1252,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+therapy+treatment&page=23&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+therapy+treatment&page=21&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T06:10:58.304Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04569747",
      "title": "A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HER2-positive Breast Cancer",
        "Invasive Carcinoma of the Breast",
        "Breast Cancer",
        "Node Negative Breast Cancer",
        "Micrometastasis Breast Cancer",
        "Hormone Receptor Positive Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Pertuzumab+TRASTUZUMAB",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "ADJUVANT ENDOCRINE THERAPY",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 393,
      "start_date": "2021-01-11",
      "completion_date": "2032-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-10-14T06:10:58.304Z",
      "location_count": 32,
      "location_summary": "Stamford, Connecticut • Miami, Florida • Atlanta, Georgia + 20 more",
      "locations": [
        {
          "city": "Stamford",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04569747"
    },
    {
      "nct_id": "NCT00025740",
      "title": "Clonazepam and Paroxetine for Rapid Treatment of Post-Traumatic Stress Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Post Traumatic Stress Disorder"
      ],
      "interventions": [
        {
          "name": "clonazepam and paroxetine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Mental Health (NIMH)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 78,
      "start_date": "2001-10",
      "completion_date": "2004-08",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-10-14T06:10:58.304Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00025740"
    },
    {
      "nct_id": "NCT03917381",
      "title": "GEN1046 Safety Trial in Patients With Malignant Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Acasunlimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Acasunlimab in combination with docetaxel (in a single expansion cohort)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Acasunlimab in combination with pembrolizumab (in a separate expansion cohort)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Genmab",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 429,
      "start_date": "2019-05-14",
      "completion_date": "2026-08-03",
      "has_results": true,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-10-14T06:10:58.304Z",
      "location_count": 14,
      "location_summary": "Phoenix, Arizona • New Haven, Connecticut • Jacksonville, Florida + 11 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03917381"
    },
    {
      "nct_id": "NCT01771107",
      "title": "Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "AIDS-Related Hodgkin Lymphoma",
        "Ann Arbor Stage II Hodgkin Lymphoma",
        "Ann Arbor Stage IIA Hodgkin Lymphoma",
        "Ann Arbor Stage IIB Hodgkin Lymphoma",
        "Ann Arbor Stage III Hodgkin Lymphoma",
        "Ann Arbor Stage IIIA Hodgkin Lymphoma",
        "Ann Arbor Stage IIIB Hodgkin Lymphoma",
        "Ann Arbor Stage IV Hodgkin Lymphoma",
        "Ann Arbor Stage IVA Hodgkin Lymphoma",
        "Ann Arbor Stage IVB Hodgkin Lymphoma",
        "Classic Hodgkin Lymphoma",
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "Brentuximab Vedotin",
          "type": "DRUG"
        },
        {
          "name": "Dacarbazine",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Vinblastine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2013-03-08",
      "completion_date": "2024-03-21",
      "has_results": true,
      "last_update_posted_date": "2025-08-15",
      "last_synced_at": "2026-10-14T06:10:58.304Z",
      "location_count": 20,
      "location_summary": "La Jolla, California • Los Angeles, California • Sacramento, California + 10 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01771107"
    },
    {
      "nct_id": "NCT07590934",
      "title": "Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "AZD2265 (FPI-2265)",
          "type": "DRUG"
        },
        {
          "name": "Palacaparib (AZD9574)",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "AZD2287 (Imaging agent)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "MALE",
        "summary": "18 Years to 99 Years · Male only"
      },
      "enrollment_count": 152,
      "start_date": "2026-06-03",
      "completion_date": "2029-09-25",
      "has_results": false,
      "last_update_posted_date": "2026-08-27",
      "last_synced_at": "2026-10-14T06:10:58.304Z",
      "location_count": 11,
      "location_summary": "Duarte, California • Encino, California • South Pasadena, California + 8 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "South Pasadena",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07590934"
    },
    {
      "nct_id": "NCT03283696",
      "title": "A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "Olaratumab",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2017-10-18",
      "completion_date": "2019-08-25",
      "has_results": true,
      "last_update_posted_date": "2020-09-10",
      "last_synced_at": "2026-10-14T06:10:58.304Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Houston, Texas",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03283696"
    },
    {
      "nct_id": "NCT00903942",
      "title": "Abraxane and RT for Non-Small Cell Lung Cancer (NSCLC)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer, Stage III"
      ],
      "interventions": [
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "Paclitaxel Protein-Bound, and CARBOPLATIN",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2008-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-04-27",
      "last_synced_at": "2026-10-14T06:10:58.304Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00903942"
    },
    {
      "nct_id": "NCT02199041",
      "title": "Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hematological Malignancies"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        },
        {
          "name": "G-CSF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Total lymphoid irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Lymphocyte infusions",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CliniMACS",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "RADIATION",
        "DEVICE"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 24,
      "start_date": "2014-07-11",
      "completion_date": "2017-05-23",
      "has_results": true,
      "last_update_posted_date": "2018-02-07",
      "last_synced_at": "2026-10-14T06:10:58.304Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02199041"
    },
    {
      "nct_id": "NCT01522222",
      "title": "Study to Determine if Using Ventilation During Open Heart Surgery Improves Lung Outcomes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Coronary Artery Disease",
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "continuous, mechanical ventilatory support",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Aurora BayCare Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 40,
      "start_date": "2010-07",
      "completion_date": "2015-09-29",
      "has_results": false,
      "last_update_posted_date": "2018-12-14",
      "last_synced_at": "2026-10-14T06:10:58.304Z",
      "location_count": 1,
      "location_summary": "Green Bay, Wisconsin",
      "locations": [
        {
          "city": "Green Bay",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01522222"
    },
    {
      "nct_id": "NCT00738751",
      "title": "Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lung Cancer",
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "Panobinostat (LBH589)",
          "type": "DRUG"
        },
        {
          "name": "erlotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2008-11",
      "completion_date": "2015-02",
      "has_results": false,
      "last_update_posted_date": "2015-02-04",
      "last_synced_at": "2026-10-14T06:10:58.304Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00738751"
    }
  ]
}